恒生创新药ETF（159316）连续12日获资金布局，规模创历史新高

Group 1 - The Hang Seng Hong Kong Stock Connect Innovative Drug Index, the CSI Innovative Drug Industry Index, and the CSI Biotechnology Theme Index all declined by 1.2%, while the CSI Hong Kong Stock Connect Medical and Health Comprehensive Index fell by 1.3%, and the CSI 300 Medical and Health Index decreased by 2.1% [1] - As of yesterday, the Hang Seng Innovative Drug ETF (159316) has seen continuous inflows for 12 trading days, with its latest scale exceeding 900 million yuan, reaching a historical high [1] Group 2 - The Hang Seng Innovative Drug ETF tracks the Hang Seng Hong Kong Stock Connect Innovative Drug Index, which focuses on leading innovative drug companies in the Hong Kong stock market, composed of no more than 40 stocks involved in innovative drug research, development, and production [2] - The index has experienced a decline of 1.2% with a rolling P/E ratio of 35.3 times as of July 10, 2023 [2] - The Hong Kong Stock Connect Medical ETF tracks the CSI Hong Kong Stock Connect Medical and Health Comprehensive Index, which focuses on leading companies in the medical and health sector, composed of 50 stocks from medical devices, biopharmaceuticals, and chemical drugs [2] - This index has also declined by 1.3% with a rolling P/E ratio of 33.5 times, and it has a valuation percentile of 50.7% since its inception in 2017 [2]